This page contains a Flash digital edition of a book.
Creating knowledge- rich value from data

Small molecule chemistry R&D is a relatively traditional subset of Scientific Computing World. Daria Torp looks to see if there is change ahead


dvanced Chemistry Development (ACD/Labs) shares this 20th anniversary with Scientific Computing World, having been established in 1994

with a handful of chemistry-focused soſtware applications. Our focus and product portfolio have changed to reflect customer demands such as improved productivity, knowledge retention, broader global access to information, and an overall need for faster chemistry discovery and insight. Computing devices have become an integral part of the chemistry research and development process and are no longer viewed as a panacea, nor a threat. Te business environment is demanding

and increasingly global, a trend likely to continue. Twenty years ago, customers used our predictive modelling soſtware to help with insight; and to eliminate erroneous directions by, for example, predicting the physicochemical properties of future drug candidates that might adversely affect product bioavailability. While still relying on various predictive models and interpretative/analytical tools, customers are

The ACD/Spectrus platform provides an environment for processing, analysis, and interpretation of multi- technique, multi-vendor analytical data; stored in chemical context for instant re-use

now also demanding instant access to existing knowledge to drive decisions. Scientists and their organisations want real-time access to their colleagues’/partners’ findings whether they are down the corridor or overseas. Easy access

to legacy problem-solving is also a valuable resource for more efficient science. Similarly there is a growing demand for

intelligent ‘silent automation’ to remove non- value added tasks. Scientists complain they have no time to be inventive and insightful under the barrage of tedious routine duties. ACD/Labs’ recent Symposium on Laboratory

ACD/Percepta delivers data mining, visualisation, and decision-support for scientists that exploit chemical property information to drive project


Intelligence brought together scientists from various industries, and automation was a hot topic. Chemists from GlaxoSmithKline, Eli Lilly, AstraZeneca, and Lexicon Pharmaceuticals chaired a panel discussion on Automated Structure Verification (ASV). Tis technology automates the process of chemical structure verification/confirmation by combining automated processing of data and knowledge-driven interpretation, to evaluate the match between a chemical entity and acquired spectral measurements. ASV has been employed to evaluate the quality of outsourced or commercially available synthetic building blocks (a problem that has gained widespread attention in recent years) and is useful in reducing the heavy burden of routine spectroscopic data interpretation in analytical labs. Te panel agreed this technology is

@scwmagazine l

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45